{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:16:27Z","timestamp":1792653387312,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd008940.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000}}],"reference-count":141,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd008940.pub3","type":"journal-article","created":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T09:46:43Z","timestamp":1548668803000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Pharmacotherapies for cannabis dependence"],"prefix":"10.1002","volume":"2020","author":[{"given":"Suzanne","family":"Nielsen","sequence":"first","affiliation":[{"name":"Monash University; Monash Addiction Research Centre; Peninsula Campus McMahons Road Frankston VIC Australia 3199"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Gowing","sequence":"additional","affiliation":[{"name":"University of Adelaide; Discipline of Pharmacology; Frome Road Adelaide South Australia Australia 5005"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Sabioni","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health; University of Toronto; Translational Addiction Research Laboratory; 33 Russell Street Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health; University of Toronto; Translational Addiction Research Laboratory; 33 Russell Street Toronto ON Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0002|cit2","first-page":"27","article-title":"The impact of Sativex (R) on cognitive function during treatment for cannabis withdrawal","volume":"32","author":"Bruno","year":"2013","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11419-016-0330-0","article-title":"Urinary cannabinoid levels during nabiximols (Sativex\u00ae)-medicated inpatient cannabis withdrawal","volume":"35","author":"Kevin","year":"2017","journal-title":"Forensic Toxicology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD008940.pub3-BIB0004|cit4","first-page":"79","article-title":"Cannabinoid replacement therapy for management of cannabis withdrawal: a randomized controlled trial of nabiximols (Sativex\u00ae)","volume":"48","author":"Montebello","year":"2014","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/10550490802408936","article-title":"A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence","volume":"18","author":"Carpenter","year":"2009","journal-title":"American Journal on Addictions"},{"issue":"1-2","key":"10.1002\/14651858.CD008940.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.drugalcdep.2010.05.010","article-title":"Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults","volume":"112","author":"Cornelius","year":"2010","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0007|cit7","first-page":"109","article-title":"Treatment trial and long-term follow-up evaluation among co-morbid youth with major depression and a cannabis use disorder","volume":"93","author":"Cornelius","year":"2012","journal-title":"Advances in Psychology Research"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0008|cit8","unstructured":"Frewen A Montebello ME Baillie A Rea F Effects of mirtazapine on withdrawal from dependent cannabis use 69th Annual Scientific Meeting of the College on Problems of Drug Dependence; 2007 June 16-21; Quebec City, Canada 2007 21 FREWEN2007"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0009|cit9","volume-title":"An Examination of Withdrawal Symptoms and their Relationship with Outcomes in a Combined Behavioural and Pharmacological Intervention for Dependent Cannabis Users [thesis]","author":"Frewen","year":"2009"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jsat2015.12.003","article-title":"Low pretreatment impulsivity and high medication adherence increase the odds of abstinence in a trial of N-acetylcysteine in adolescents with cannabis use disorder","volume":"63","author":"Bentzley","year":"2016","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1176\/appi.ajp.2012.12010055","article-title":"A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents","volume":"169","author":"Gray","year":"2012","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3109\/00952990.2013.878718","article-title":"Cigarette smoking during an N-acetylcysteine-assisted cannabis cessation trial in adolescents","volume":"40","author":"McClure","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.addbeh.2015.01.013","article-title":"Cognitive performance in a placebo-controlled pharmacotherapy trial for youth with marijuana dependence","volume":"45","author":"Roten","year":"2015","journal-title":"Addictive Behaviors"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/j.addbeh.2012.11.003","article-title":"Marijuana craving trajectories in an adolescent marijuana cessation pharmacotherapy trial","volume":"38","author":"Roten","year":"2013","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1016\/j.drugalcdep.2016.08.533","article-title":"Alcohol use during an N-acetylcysteine cannabis cessation trial in adolescents","volume":"171","author":"Squeglia","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.addbeh.2016.08.001","article-title":"Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation","volume":"63","author":"Squeglia","year":"2016","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cct.2014.08.011","article-title":"Achieving Cannabis Cessation \u2013 Evaluating N-acetylcysteine Treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network","volume":"39","author":"McClure","year":"2014","journal-title":"Contemporary Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/ajad.12503","article-title":"Gender differences among treatment-seeking adults with cannabis use disorder: Clinical profiles of women and men enrolled in the Achieving Cannabis Cessation \u2013 Evaluating N-acetylcysteine Treatment (ACCENT) study","volume":"26","author":"Sherman","year":"2017","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.drugalcdep.2017.12.005","article-title":"The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial","volume":"185","author":"Squeglia","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.5664\/jcsm.5090","article-title":"The effects of lithium carbonate supplemented with nitrazepam on sleep disturbance during cannabis abstinence","volume":"11","author":"Allsop","year":"2015","journal-title":"Journal of Clinical Sleep Medicine"},{"issue":"24","key":"10.1002\/14651858.CD008940.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00213-014-3611-5","article-title":"Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting","volume":"231","author":"Johnston","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0023|cit23","first-page":"43","article-title":"A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [conference abstract]","volume":"32","author":"Johnston","year":"2013","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0024|cit24","first-page":"45","article-title":"Preliminary findings from a double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal [conference abstract]","volume":"31","author":"Johnston","year":"2012","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/10550490490265280","article-title":"Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium","volume":"13","author":"Levin","year":"2004","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial","volume":"116","author":"Levin","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.drugalcdep.2014.06.040","article-title":"Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?","volume":"144","author":"Kelly","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/add.12108","article-title":"A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders","volume":"108","author":"Levin","year":"2013","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugalcdep.2015.11.025","article-title":"Dronabinol and lofexidine for cannabis use disorder: a randomized, double-blind, placebo-controlled trial","volume":"159","author":"Levin","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jsat.2015.05.002","article-title":"Concordance of direct and indirect measures of medication adherence in a treatment trial for cannabis dependence","volume":"57","author":"McRae-Clark","year":"2015","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.drugalcdep.2009.06.022","article-title":"A placebo-controlled trial of buspirone for the treatment of marijuana dependence","volume":"105","author":"McRae-Clark","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/j.1521-0391.2010.00076.x","article-title":"A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder","volume":"19","author":"McRae-Clark","year":"2010","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.drugalcdep.2015.08.013","article-title":"Buspirone treatment of cannabis dependence: a randomized, placebo-controlled trial","volume":"156","author":"McRae-Clark","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.addbeh.2016.04.014","article-title":"Gender differences in cannabis use disorder treatment: change readiness and taking steps predict worse cannabis outcomes for women","volume":"60","author":"Sherman","year":"2016","journal-title":"Addictive Behaviors"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1111\/ajad.12324","article-title":"Vilazodone for cannabis dependence: a randomized, controlled pilot trial","volume":"25","author":"McRae-Clark","year":"2016","journal-title":"American Journal on Addictions"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/JCP.0000000000000843","article-title":"Predictors of topiramate tolerability in heavy cannabis-using adolescents and young adults: a secondary analysis of a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Gray","year":"2018","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/adb.12350","article-title":"Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study","volume":"22","author":"Miranda","year":"2017","journal-title":"Addiction Biology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0039|cit39","first-page":"265A","article-title":"Effects of topiramate on cannabis use among youth: an initial proof-of concept trial in the natural environment","volume":"39","author":"Treloar","year":"2015","journal-title":"Alcoholism: Clinical and Experimental Research"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0040|cit40","first-page":"63","article-title":"Bupropion reduces some of the symptoms of marihuana withdrawal in chronic marihuana users: a pilot study","volume":"6","author":"Penetar","year":"2012","journal-title":"Substance Abuse: Research and Treatment"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.psychres.2017.01.027","article-title":"Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention","volume":"249","author":"Sherman","year":"2017","journal-title":"Psychiatry Research"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"S422","DOI":"10.1038\/npp.2016.241","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence, a pilot study","volume":"41","author":"Trigo","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s13311-017-0543-x","article-title":"Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence: a pilot randomized clinical trial","volume":"14","author":"Trigo","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"e0190768","DOI":"10.1371\/journal.pone.0190768","article-title":"Nabiximols combined with motivational enhancement\/cognitive behavioral therapy for the treatment of cannabis dependence: a pilot randomized clinical trial","volume":"13","author":"Trigo","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3109\/00952990.2013.819362","article-title":"Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study","volume":"40","author":"Weinstein","year":"2014","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/02791072.2017.1370746","article-title":"Feasibility and preliminary effectiveness of varenicline for treating co-occurring cannabis and tobacco use","volume":"50","author":"Adams","year":"2018","journal-title":"Journal of Psychoactive Drugs"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1080\/10550490701389658","article-title":"Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia","volume":"16","author":"Akerele","year":"2007","journal-title":"American Journal on Addictions"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jsat.2012.08.223","article-title":"Initiation of abstinence in adolescents treated for marijuana use disorders","volume":"44","author":"Brown","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.drugalcdep.2006.04.014","article-title":"Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms","volume":"86","author":"Budney","year":"2007","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1369-1600.2012.00461.x","article-title":"A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers","volume":"18","author":"Cooper","year":"2013","journal-title":"Addiction Biology"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0306-4603(98)00050-1","article-title":"Fluoxetine versus placebo for the marijuana use of depressed alcoholics","volume":"24","author":"Cornelius","year":"1999","journal-title":"Addictive Behaviours"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub3-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.addbeh.2008.02.001","article-title":"Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence","volume":"33","author":"Cornelius","year":"2008","journal-title":"Addictive Behaviors"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.drugalcdep.2015.07.1050","article-title":"Mirtazapine pilot trial in comorbid MDD\/SUD: long-term follow-up results","volume":"156","author":"Cornelius","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0054|cit54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1753-2000-3-11","article-title":"The short-term safety and efficacy of fluoxetine in depressed adolescents with alcohol and cannabis use disorders: a pilot randomized placebo-controlled trial","volume":"3","author":"Findling","year":"2009","journal-title":"Child and Adolescent Psychiatry and Mental Health"},{"issue":"4","key":"10.1002\/14651858.CD008940.pub3-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jsat.2011.09.010","article-title":"Moderators of fluoxetine treatment response for children and adolescents with comorbid depression and substance use disorders","volume":"42","author":"Hirschtritt","year":"2012","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004583-199802000-00009","article-title":"Double-blind and placebo-controlled study of lithium for adolescent bipolar disorders with secondary substance dependency","volume":"37","author":"Geller","year":"1998","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0278-5846(92)90080-X","article-title":"Early findings from a pharmacokinetically designed double-blind and placebo-controlled study of lithium for adolescents comorbid with bipolar and substance dependency disorders","volume":"16","author":"Geller","year":"1992","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1080\/00207450600753998","article-title":"Combined cannabis\/methaqualone withdrawal treated with psychotropic analgesic nitrous oxide","volume":"116","author":"Gillman","year":"2006","journal-title":"International Journal of Neuroscience"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1521-0391.2009.00027.x","article-title":"N-Acetylcysteine (NAC) in young marijuana users: an open-label pilot study","volume":"19","author":"Gray","year":"2010","journal-title":"American Journal on Addictions"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002130000657","article-title":"Bupropion SR worsens mood during marijuana withdrawal in humans","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-002-1210-3","article-title":"Nefazodone decreases anxiety during marijuana withdrawal in humans","volume":"165","author":"Haney","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0062|cit62","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00213-002-1279-8","article-title":"Interaction between naltrexone and oral THC in heavy marijuana smokers","volume":"166","author":"Haney","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.npp.1300310","article-title":"Marijuana withdrawal in humans: effects of oral THC or divalproex","volume":"29","author":"Haney","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-010-1888-6","article-title":"Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse","volume":"211","author":"Haney","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0067|cit66","first-page":"S277","article-title":"Nabilone dose-response in marijuana smokers: comparison to dronabinol","volume":"35","author":"Haney","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0066|cit67","doi-asserted-by":"publisher","first-page":"S177","DOI":"10.1038\/npp.2011.291","article-title":"Nabilone decreases marijuana withdrawal and relapse in the human laboratory","volume":"36","author":"Haney","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub3-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1038\/npp.2013.54","article-title":"Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"10.1002\/14651858.CD008940.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/npp.2015.108","article-title":"Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers","volume":"40","author":"Haney","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.drugalcdep.2016.11.030","article-title":"Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers","volume":"172","author":"Babalonis","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.drugalcdep.2015.07.954","article-title":"Examination of the behavioral effects of oral cannabidiol alone and in combination with smoked marijuana","volume":"156","author":"Babalonis","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1002\/14651858.CD008940.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1038\/npp.2015.367","article-title":"Oral cannabidiol does not alter the subjective, reinforcing or cardiovascular effects of smoked cannabis","volume":"41","author":"Haney","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"S508","DOI":"10.1038\/npp.2013.281","article-title":"Marijuana withdrawal and relapse in the human laboratory: effect of zolpidem alone and in combination with nabilone","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1016\/j.drugalcdep.2016.08.247","article-title":"Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and relapse among non-treatment-seeking cannabis users","volume":"171","author":"Herrmann","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"issue":"13","key":"10.1002\/14651858.CD008940.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1007\/s00213-016-4298-6","article-title":"Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users","volume":"233","author":"Herrmann","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.biopsych.2010.03.033","article-title":"Baclofen in cannabis dependence syndrome","volume":"68","author":"Nanjayya","year":"2010","journal-title":"Biological Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1080\/00952990.2017.1423321","article-title":"Open-label pilot study of injectable naltrexone for cannabis dependence","volume":"44","author":"Notzon","year":"2018","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4321\/S0213-61632006000300001","article-title":"Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study","volume":"20","author":"Rubio","year":"2006","journal-title":"European Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1521-0391.2014.12126.x","article-title":"Ziprasidone versus clozapine in the treatment of dually diagnosed (DD) patients with schizophrenia and cannabis use disorders: a randomized study","volume":"23","author":"Schnell","year":"2014","journal-title":"American Journal on Addictions"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.psychres.2011.05.001","article-title":"Olanzapine vs risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes","volume":"188","author":"Sevy","year":"2011","journal-title":"Psychiatry Research"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pbb.2010.12.013","article-title":"The safety of modafinil in combination with oral 9-tetrahydrocannabinol in humans","volume":"98","author":"Sugarman","year":"2011","journal-title":"Pharmacology, Biochemistry and Behavior"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.drugalcdep.2016.02.020","article-title":"Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings","volume":"161","author":"Trigo","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.drugalcdep.2011.01.003","article-title":"Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal","volume":"117","author":"Vandrey","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"issue":"1-2","key":"10.1002\/14651858.CD008940.pub3-BIB0084|cit84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.drugalcdep.2012.08.001","article-title":"The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users","volume":"128","author":"Vandrey","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub3-BIB0086|cit85","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1016\/j.jaac.2016.07.696","article-title":"Cannabis withdrawal and sleep disturbance: implications for the treatment of cannabis use disorder","volume":"55","author":"Vandrey","year":"2016","journal-title":"Journal of the American Academy of Child and Adolescent Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0085|cit86","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1016\/j.drugalcdep.2014.09.708","article-title":"A pilot study of zolpidem pharmacotherapy in the treatment of cannabis use disorders","volume":"146","author":"Vandrey","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/070674370805300610","article-title":"Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial","volume":"53","author":"Nimwegen","year":"2008","journal-title":"Canadian Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1177\/0269881108089584","article-title":"Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study","volume":"23","author":"Winstock","year":"2009","journal-title":"Journal of Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12888-018-1682-2","article-title":"Randomised controlled trial (RCT) of cannabinoid replacement therapy (nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol","volume":"18","author":"Bhardwaj","year":"2018","journal-title":"BMC Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0091|cit90","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1038\/npp.2017.263","article-title":"FAAH inhibitor PF-04457845 in the treatment of cannabis dependence","volume":"43","author":"D'Souza","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0090|cit91","first-page":"S437","article-title":"FAAH inhibitor treatment for cannabis dependence","volume":"40","author":"D'Souza","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0092|cit92","unstructured":"NCT00974376 Gabapentin treatment of cannabis dependence clinicaltrials.gov\/ct2\/show\/NCT00974376"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0093|cit93","unstructured":"NCT01598896 Combination of dronabinol and clonidine for cannabis dependence in patients with schizophrenia clinicaltrials.gov\/show\/NCT01598896"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0094|cit94","unstructured":"NCT02044809 Cannabidiol: a novel intervention for cannabis use problems? clinicaltrials.gov\/ct2\/show\/NCT02044809"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0095|cit95","unstructured":"NCT02579421 Hormones and reduction in co-users of marijuana and nicotine clinicaltrials.gov\/show\/NCT02579421"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0096|cit96","doi-asserted-by":"crossref","unstructured":"Agrawal A Pergadia ML Lynskey MT Is there evidence for symptoms of cannabis withdrawal in the National Epidemiologic Survey of Alcohol and Related Conditions? American Journal on Addictions 2008 199 208","DOI":"10.1080\/10550490802019519"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0097|cit97","doi-asserted-by":"crossref","unstructured":"Beauvais F Jumper-Thurman P Helm H Plested B Burnside M Surveillance of drug use among American Indian adolescents: patterns over 25 years Journal of Adolescent Health 2004 493 500","DOI":"10.1016\/j.jadohealth.2003.07.019"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/14737175.8.3.479","article-title":"Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence","volume":"8","author":"Benyamina","year":"2008","journal-title":"Expert Review of Neurotherapeutics"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0099|cit99","doi-asserted-by":"crossref","unstructured":"Budney AJ Moore BA Vandrey RG Hughes JR The time course and significance of cannabis withdrawal Journal of Abnormal Psychology 2003 393 402","DOI":"10.1037\/0021-843X.112.3.393"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0100|cit100","doi-asserted-by":"crossref","unstructured":"Budney AJ Hughes JR The cannabis withdrawal syndrome Current Opinion in Psychiatry 2006 233 8","DOI":"10.1097\/01.yco.0000218592.00689.e5"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Budney AJ Roffman R Stephens RS Walker D Marijuana dependence and its treatment Addiction Science & Clinical Practice 2007 4 16","DOI":"10.1151\/ASCP07414"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0102|cit102","doi-asserted-by":"crossref","unstructured":"Chung T Martin CS Cornelius JR Clark DB Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents Addiction 2008 787 99","DOI":"10.1111\/j.1360-0443.2008.02158.x"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0103|cit103","doi-asserted-by":"crossref","unstructured":"Clough AR D'Abbs P Cairney S Gray D Maruff P Parker R Emerging patterns of cannabis and other substance use in Aboriginal communities in Arnhem Land, Northern Territory: a study of two communities Drug and Alcohol Review 2004 381 90","DOI":"10.1080\/09595230412331324509"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0104|cit104","doi-asserted-by":"crossref","unstructured":"Copeland J Swift W Rees V Clinical profile of participants in a brief intervention program for cannabis use disorder Journal of Substance Abuse Treatment 2001 45 52","DOI":"10.1016\/S0740-5472(00)00148-3"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0105|cit105","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/npy.13.90","article-title":"Cannabis use, harms and the management of cannabis use disorder","volume":"4","author":"Copeland","year":"2014","journal-title":"Neuropsychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0106|cit106","doi-asserted-by":"crossref","unstructured":"Copersino ML Boyd SJ Tashkin DP Huestis MA Heishman SJ Dermand JC Cannabis withdrawal among non-treatment-seeking adult cannabis users American Journal on Addictions 2006 8 14","DOI":"10.1080\/10550490500418997"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.psc.2012.03.003","article-title":"State of the art treatments for cannabis dependence","volume":"35","author":"Danovitch","year":"2012","journal-title":"Psychiatric Clinics of North America"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0108|cit108","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition dsm.psychiatryonline.org 2013","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0109|cit109","unstructured":"European Monitoring Centre for Drugs and Drug Addiction Cannabis problems in context: understanding the increase in European treatment demands www.emcdda.europa.eu\/html.cfm\/index34898EN.html 2004 81 92"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0110|cit110","unstructured":"European Monitoring Centre for Drugs and Drug Addiction Cannabis drug profile www.emcdda.europa.eu\/publications\/drug-profiles\/cannabis"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub3-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005336.pub4","article-title":"Psychosocial interventions for cannabis use disorder","author":"Gates","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"42","key":"10.1002\/14651858.CD008940.pub3-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"6409","DOI":"10.2174\/1381612822666160822150822","article-title":"Pharmacological treatment of cannabis-related disorders: a narrative review","volume":"22","author":"Gorelick","year":"2016","journal-title":"Current Pharmaceutical Design"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0113|cit113","doi-asserted-by":"crossref","unstructured":"Gruber AJ Pope HG Hudson JI Yurgelun-Todd D Attributes of long-term heavy cannabis users: a case-control study Psychological Medicine 2003 1415 22","DOI":"10.1017\/S0033291703008560"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0114|cit114","volume-title":"The Health and Psychological Effects of Cannabis Use","author":"Hall","year":"2001"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0115|cit115","doi-asserted-by":"crossref","unstructured":"Hall W Degenhardt L Adverse health effects of non-medical cannabis use Lancet 2009 1383 91","DOI":"10.1016\/S0140-6736(09)61037-0"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0116|cit116","doi-asserted-by":"crossref","unstructured":"Hart CL Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies Drug and Alcohol Dependence 2005 147 59","DOI":"10.1016\/j.drugalcdep.2005.03.027"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0117|cit117","doi-asserted-by":"crossref","unstructured":"Hasin DS Keyes KM Alderson D Wang S Aharonovich E Grant BF Cannabis withdrawal in the United States: results from NESARC Journal of Clinical Psychiatry 2008 1354 63","DOI":"10.4088\/JCP.v69n0902"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0118|cit118","unstructured":"Higgins JP Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011 Available from handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD008940.pub3-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/archgenpsychiatry.2011.5","article-title":"Cannabis use and earlier onset of psychosis","volume":"68","author":"Large","year":"2011","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1521-0391.2013.00321.x","article-title":"Gender differences in prevalence of substance use disorders among individuals with lifetime exposure to substances: results from a large representative sample","volume":"22","author":"Lev-Ran","year":"2013","journal-title":"American Journal on Addictions"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.comppsych.2012.12.021","article-title":"Cannabis use and cannabis use disorders among individuals with mental illness","volume":"54","author":"Lev-Ran","year":"2013","journal-title":"Comprehensive Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD008940.pub3-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40501-015-0038-5","article-title":"Outcome measures in medication trials for substance use disorders","volume":"2","author":"McCann","year":"2015","journal-title":"Current Treatment Options in Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s00213-011-2480-4","article-title":"Characterizing smoking topography of cannabis in heavy users","volume":"220","author":"McClure","year":"2012","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub3-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004837.pub3","article-title":"Cannabis and schizophrenia","author":"McLoughlin","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0125|cit125","doi-asserted-by":"crossref","unstructured":"Milin R Manion I Dare G Walker S Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study Journal of the American Academy of Child and Adolescent Psychiatry 2008 174 9","DOI":"10.1097\/CHI.Ob013e31817eed9e"},{"issue":"3","key":"10.1002\/14651858.CD008940.pub3-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1465-3362.2009.00132.x","article-title":"An overview of systematic reviews on cannabis and psychosis: discussing apparently conflicting results","volume":"29","author":"Minozzi","year":"2010","journal-title":"Drug and Alcohol Review"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0127|cit127","doi-asserted-by":"crossref","unstructured":"Nordstrom BR Levin FR Treatment of cannabis use disorders: a review of the literature American Journal on Addictions 2007 331 42","DOI":"10.1080\/10550490701525665"},{"issue":"10","key":"10.1002\/14651858.CD008940.pub3-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0129|cit129","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0130|cit130","article-title":"Treatment Episode Data Set (TEDS): 1996-2006. National Admissions to Substance Abuse Treatment Services","volume-title":"www.oas.samhsa.gov\/copies.cfm","author":"Substance Abuse and Mental Health Services Administration","year":"2008"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0131|cit131","unstructured":"Sch\u0171nemann H Brozek J Guyatt G Oxman A editor(s) GRADE handbook for grading quality of evidence and strength of recommendations. The GRADE Working Group, 2013 gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"5","key":"10.1002\/14651858.CD008940.pub3-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/phar.1747","article-title":"Treatment of cannabis use disorder: current science and future outlook","volume":"36","author":"Sherman","year":"2016","journal-title":"Reviews of Therapeutics"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S2215-0366(14)70307-4","article-title":"Young adult sequelae of adolescent cannabis use: an integrative analysis","volume":"1","author":"Silins","year":"2014","journal-title":"Lancet Psychiatry"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drugalcdep.2015.08.034","article-title":"Adolescent substance use and educational attainment: an integrative data analysis comparing cannabis and alcohol from three Australasian cohorts","volume":"156","author":"Silins","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1002\/14651858.CD008940.pub3-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/1874473710801010081","article-title":"The chronic effects of cannabis on memory in humans: a review","volume":"1","author":"Solowij","year":"2008","journal-title":"Current Drug Abuse Reviews"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/add.12508","article-title":"Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study","volume":"109","author":"Pol","year":"2014","journal-title":"Addiction"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0137|cit137","doi-asserted-by":"crossref","unstructured":"Vandrey R Haney M Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009 543 53","DOI":"10.2165\/00023210-200923070-00001"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMra1402309","article-title":"Adverse health effects of marijuana use","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"39","key":"10.1002\/14651858.CD008940.pub3-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3238\/arztebl.2016.0653","article-title":"Evidence-based treatment options in cannabis dependency","volume":"113","author":"Walther","year":"2016","journal-title":"Deutsches \u00c4rzteblatt International"},{"key":"10.1002\/14651858.CD008940.pub3-BIB0140|cit140","unstructured":"United Nations Office on Drugs and Crime World Drug Report 2017 www.unodc.org\/wdr2017"},{"issue":"12","key":"10.1002\/14651858.CD008940.pub3-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008940.pub2","article-title":"Pharmacotherapies for cannabis dependence","author":"Marshall","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd008940.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD008940.pub3\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T16:45:50Z","timestamp":1743007550000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD008940.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Drugs and Alcohol Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":141,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd008940.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]}}}